Wave Life Sciences Ltd. (WVE)
| Market Cap | 244.56M |
| Revenue (ttm) | 42.71M |
| Net Income (ttm) | -117.60M |
| Shares Out | 86.72M |
| EPS (ttm) | -2.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,423,304 |
| Open | 2.43 |
| Previous Close | 2.40 |
| Day's Range | 2.35 - 2.85 |
| 52-Week Range | 1.16 - 7.24 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 8.74 (+209.9%) |
| Earnings Date | Aug 4, 2022 |
About WVE
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin ... [Read more...]
Financial Performance
In 2021, WVE's revenue was $40.96 million, an increase of 104.03% compared to the previous year's $20.08 million. Losses were -$122.25 million, -18.45% less than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for WVE stock is "Buy." The 12-month stock price forecast is 8.74, which is an increase of 209.93% from the latest price.
News
Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering
CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling ...
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -10.71% and 53.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
Delivered first clinical data demonstrating target engagement and translation of PN chemistry's impact in clinic; Adapting ongoing Phase 1b/2a FOCUS-C9 clinical trial to optimize dose level and frequenc...
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling ...
Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling ...
Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf...
Preclinical data published in Molecular Therapy Nucleic Acids demonstrate that WVE-004 potently reduces C9orf72 transcriptional variants and poly(GP) dipeptide repeat proteins in mice for at least six m...
Wave Life Sciences to Present at Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battlin...
Wave Life Sciences Jump As Low Doses of WVE-004 Lowers Disease Biomarker In Neurological Indications
Wave Life Sciences Ltd's (NASDAQ: WVE) FOCUS-C9 study of WVE-004 shows reductions of poly(GP) dipeptide repeat proteins in cerebrospinal fluid (CSF) with low, single doses of WVE-004. The Phase 1b/2a t...
Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductio...
Reductions in poly(GP), a key disease biomarker indicating target engagement, observed across all treatment groups after single doses
Wave Life Sciences to Present at Stifel 2022 CNS Days
CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battlin...
Wave Life Sciences to Highlight RNA Base Editing Modality and Alpha-1 Antitrypsin Deficiency Program at Upcoming Scie...
Presentation at OPT 2022 to highlight AATD program, including reduction of liver aggregates with repeat AIMer dosing out to 19 weeks
Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primat...
Published data demonstrate potent, durable, and specific editing and potential for therapeutic applications in liver using a subcutaneous GalNAc-conjugated oligonucleotide approach
Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -29.79% and 90.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Clinical data from multiple novel, PN-modified stereopure oligonucleotides for ALS/FTD, DMD, and HD expected in 2022
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Mo...
Wave paper on PN chemistry for silencing in the CNS, and the implications for oligonucleotides more broadly, designated as a Breakthrough Article by Nucleic Acids Research
Two Organizations To Support Wave Life Sciences' FTD, ALS Program
The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) will support Wave Life Sciences Ltd's amyotrophic lateral sclerosis (ALS) and frontotemporal d...
ADDF and AFTD Partner to Support Wave Life Sciences' FTD and ALS Clinical Program
NEW YORK, Jan. 25, 2022 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced today that they have partnered to support Wa...
Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of 81.25% and 240.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update
Strengthened balance sheet with approximately $52 million; focusing additional investment in RNA editing programs led by hepatic editing
Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...
Will Wave Life Sciences (WVE) Report Negative Q3 Earnings? What You Should Know
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021
CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...